Emergex

Share on: 
Website: Emergex
Business Area(s): 
Description: 

Developing set-point vaccines against viral and bacterial infectious diseases, using purely synthetic non-biological components that prime immune cells to destroy pathogen infected cells. Emergex has successfully generated a 1st generation human specific MHC-Class I CD8 peptide ‘ligandome’ library for Dengue, Influenza, Zika, Hepatitis B and Francisella tularensis, for the most commonly occurring human alleles.

Location(s): 
Headquarters
Abingdon
United Kingdom
R&D
Abingdon
United Kingdom